Nanostart holding Lumiphore and Algeta announce expansion of their partnership in the development of receptor-controlled radio-pharmaceuticals and companion Diagnostics to Frankfurt/Richmond, 02 may 2013 American Nanostart involving Lumiphore announced today that Algeta, a leading specialist on the radiotherapy of cancer company from Norway, its license option for the use of patented Lumi4 chelator technology has exercised. Algeta this makes use of the already 2010 closed license agreement with Lumiphore, expanding it to more Chelatfamilien. This involves, above all, to integrate the Lumi4 technology in the receptor-controlled radiotherapy (targeted radiotherapeutics) Algeta. Contact information is here: The Hague. The Lumi4 technology is based on a unique class of bi-functional Chelators, which forms a kind of cage structure to a radioactive molecule and at the same time has the ability to bind to a number of different vector molecules, such as monoclonal antibodies. These are in turn capable of detecting tumor cells and to baste them specifically.
Already in 2010, Algeta signed a license agreement with Lumiphore, that the option admitted the company to make use of the Lumi4 technology. After a long test phase successfully completed, Algeta solved this option. Parallel to this license agreement, Algeta has now purchased another license option by Lumiphore for a second class of bi-functional Chalatoren. With these, Algeta has the potential to develop companion in-vivo Diagnostics for nuclear medicine Imaging. “The goal of Lumiphore is the advantages of bi functional metal-chelate technology over to bring a variety of synthetic designs on the therapeutic markets, which use receptor-controlled radio-pharmaceuticals to treat cancer through the tumorizide effect of radionuclide microwave irradiation.